Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 10/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.31 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20025183 | 0.99 | ITGAV (0.35) | ITGAVITGB3MPOITGB6FGFR4 | |
| SCHEMBL20158186 | 0.93 | MPO (0.36) | ITGAVMPOITGB6FGFR4RAB9A | |
| SCHEMBL25352180 | 0.87 | ITGAV (0.38) | ITGAVITGB3MPOITGB6FGFR4 | |
| SCHEMBL28701882 | 0.87 | ITGAV (0.38) | ITGAVITGB3ITGB6FGFR4ITGB5 | |
| SCHEMBL27406319 | 0.87 | MPO (0.37) | MPOFGFR4RAB9AGPR119BRD4 | |
| SCHEMBL16607380 | 0.87 | ITGAV (0.40) | ITGAVITGB3MPOITGB6GPR119 | |
| SCHEMBL21317504 | 0.86 | MPO (0.39) | ITGAVMPOITGB6FGFR4RAB9A | |
| SCHEMBL20025181 | 0.86 | ITGAV (0.38) | ITGAVITGB3MPOITGB6FGFR4 | |
| SCHEMBL22223394 | 0.86 | ITGAV (0.40) | ITGAVITGB3MPOITGB6GPR119 | |
| SCHEMBL30474548 | 0.86 | ITGAV (0.40) | ITGAVITGB3MPOITGB6GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-04-01 | — | — | US | disclosed |
| WO-2020146521-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | ITGAV 1/4885ITGB3 4/4885MPO 4809/4885 |
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | ITGAV 7/4885ITGB3 10/4885MPO 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.